Form 4: Mersana Therapeutics Executive Sells Shares to Cover Tax Obligations After RSU Vesting

Sentiment:

SEC Form 4 Filing


Mohan Bala, SVP and Chief Development Officer at Mersana Therapeutics, sold shares to cover tax obligations following the vesting of restricted stock units.

Summary

  • On October 25, 2024, Mohan Bala, SVP, Chief Development Officer of Mersana Therapeutics, had 6,250 restricted stock units (RSUs) vest.
  • These RSUs converted into 6,250 shares of common stock.
  • On October 28, 2024, Bala sold 1,884 shares of common stock at a price of $1.9 per share.
  • The sale was to cover tax withholding obligations related to the RSU vesting.
  • The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2023.
  • Following these transactions, Bala directly owns 54,731 shares of Mersana Therapeutics common stock and 6,250 RSUs.

Sentiment

Score: 5

Explanation: This is a neutral event. It reflects routine stock transactions by an executive to cover tax obligations. It doesn't indicate a positive or negative outlook for the company.

Future Outlook

The remaining RSUs will vest on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. Selling shares to cover tax obligations upon vesting is a common practice.

Key Dates

DateDescription
2021-10-25Date of original RSU award.
2023-05-10Date Rule 10b5-1 trading plan was adopted.
2024-10-256,250 RSUs vested and converted to common stock.
2024-10-281,884 shares sold at $1.9 per share.
2024-10-29Date of Form 4 filing.
2025-10-25Remaining RSUs will vest, subject to continued service.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.